Does intrathecal morphine in the treatment of cancer pain induce the development of tolerance?

OBJECTIVE This retrospective study was designed to investigate whether chronic lumbar intrathecal administration of morphine leads to the development of opioid tolerance in patients suffering from intractable cancer pain. METHODS Between 1978 and 1995, 159 patients with refractory cancer pain were treated with intrathecal morphine in our Multidisciplinary Pain Center. The treatment consisted of preservative-free morphine administered through an access port as a single bolus. In this series of patients (n = 159), the daily doses of intrathecal morphine were determined as a function of duration of follow-up. RESULTS The mean follow-up period was 95 days (range, 5-909 d), the mean starting daily dose of intrathecal morphine was 2.69 mg (range, 1-7.5 mg), and the mean terminal dose was 7.82 mg (range, 1-80 mg). The results demonstrated that only a moderate increase in daily dose of intrathecal morphine was required during the course of treatment (a two- to threefold increase for a 3-mo period). Furthermore, the dose increment was similar for patients followed up for more or less than 60 days. This increase did not result in any central opioid-related side effects, and the pain was managed satisfactorily. CONCLUSION The requirement for a moderate increase in intrathecal opioid doses reflects the development of tolerance but did not limit the patients' ability to obtain adequate analgesia during the course of their painful disease.

[1]  D. Lambert,et al.  The stimulatory effects of opioids and their possible role in the development of tolerance. , 1996, Trends in pharmacological sciences.

[2]  A. Basbaum,et al.  The development of opioid tolerance in the formalin test in the rat , 1995, PAIN®.

[3]  D. Price,et al.  Mechanisms of hyperalgesian and morphine tolerance: a current view of their possible interactions , 1995, Pain.

[4]  A. Basbaum.  Insights into the development of opioid tolerance , 1995, Pain.

[5]  H. Akil,et al.  Does chronic nociceptive stimulation alter the development of morphine tolerance? , 1995, Brain Research.

[6]  J. V. Von Roenn,et al.  Physician Attitudes and Practice in Cancer Pain Management: A Survey From the Eastern Cooperative Oncology Group , 1993, Annals of Internal Medicine.

[7]  K. Jhamandas,et al.  Opioid and substance p receptor adaptations in the rat spinal cord following sub-chronic intrathecal treatment with morphine and naloxone , 1993, Neuroscience.

[8]  J. Schramm,et al.  Dose changes in long- and medium-term intrathecal morphine therapy of cancer pain. , 1992, Neurosurgery.

[9]  T. Meuser,et al.  A long-term survey of morphine in cancer pain patients. , 1992, Journal of pain and symptom management.

[10]  Josef K. Wang.  Analgesic Effect of Intrathecally Administered Morphine , 1990, Regional anesthesia and pain medicine.

[11]  G. Guilbaud,et al.  Repeated low doses of morphine do not induce tolerance but increase the opioid antinociceptive effect in rats with a peripheral neuropathy , 1990, Brain Research.

[12]  Y. Lazorthes,et al.  Chronic intrathecal baclofen administration for control of severe spasticity. , 1990, Journal of neurosurgery.

[13]  R. Portenoy,et al.  Cancer pain. Epidemiology and syndromes , 1989, Cancer.

[14]  K. Foley.  Controversies in cancer pain medical perspectives , 1989, Cancer.

[15]  A. Herz,et al.  Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: Alterations in behavior and nociceptive thresholds , 1988, Pharmacology Biochemistry and Behavior.

[16]  D. Coombs.  Intraspinal Analgesic Infusion by Implanted Pump a , 1988, Annals of the New York Academy of Sciences.

[17]  T. Yaksh,et al.  Retrospective consideration of the doses of morphine given intrathecally by chronic infusion in 163 patients by 19 physicians , 1987, Pain.

[18]  G. Brazenor,et al.  Long term intrathecal administration of morphine: a comparison of bolus injection via reservoir with continuous infusion by implanted pump. , 1987, Neurosurgery.

[19]  R. Penn,et al.  Chronic intrathecal morphine for intractable pain. , 1987, Journal of neurosurgery.

[20]  A. Caraceni,et al.  A validation study of the WHO method for cancer pain relief , 1987, Cancer.

[21]  G. Guilbaud,et al.  Repeated low doses of morphine induce a rapid tolerance in arthritic rats but a potentiation of opiate analgesia in normal animals , 1986, Brain Research.

[22]  B. Milne,et al.  Analgesia and tolerance to intrathecal morphine and norepinephrine infusion via implanted mini-osmotic pumps in the rat , 1985, Pain.

[23]  R. Penn,et al.  Cancer pain relief using chronic morphine infusion. Early experience with a programmable implanted drug pump. , 1984, Journal of neurosurgery.

[24]  O. Ravlo,et al.  Pain treatment on outpatient basis utilizing extradural opiates. A danish multicentre study comprising 105 patients , 1983, Pain.

[25]  L. Gustafsson,et al.  Continuous intrathecal administration of morphine via an osmotic minipump in the rat , 1982, Brain Research.

[26]  W. Ensminger,et al.  Benefit from and tolerance to continuous intrathecal infusion of morphine for intractable cancer pain. , 1982, Journal of neurosurgery.

[27]  T. Yaksh.  Spinal opiate analgesia: Characteristics and principles of action , 1981, PAIN®.

[28]  M. Chauvin,et al.  PLASMA CONCENTRATION OF MORPHINE AFTER I.M., EXTRADURAL AND INTRATHECAL ADMINISTRATION , 1981 .

[29]  F. Colpaert,et al.  Can chronic pain be suppressed despite purported tolerance to narcotic analgesia? , 1979, Life sciences.

[30]  Y. Lazorthes,et al.  Advances in drug delivery systems and applications in neurosurgery. , 1991, Advances and technical standards in neurosurgery.

[31]  Twycross Rg.  Opioid analgesics in cancer pain: current practice and controversies. , 1988 .

[32]  Y. Lazorthes,et al.  Spinal versus intraventricular chronic opiate administration with implantable drug delivery devices for cancer pain. , 1985, Applied neurophysiology.